Abstract
Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Central Nervous System Agents in Medicinal Chemistry
Title: Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Volume: 11 Issue: 2
Author(s): Lei Lv, Yu-Ping Tang, Xiang Han, Xin Wang and Qiang Dong
Affiliation:
Keywords: Histone deacetylase inhibitors, stroke, histone, histone deacetylase (HDAC), histone acetyltransferase (HAT), valproic acid (VPA), sodium butyrate (SB), sodium phenylbutyrate (NaPB), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), neuroprotection, chromatin, intracerebral hemorrhage (ICH), cerebral ischemia (CI), apoptosis, neuroinflammation, excitotoxicity, oxidative stress, neurotrophin, neurogenesis, histone acetylation, clinical randomed trial (RCT), central nervous system (CNS), brain edema, epidemiology
Abstract: Histone deacetylases (HDACs) play a key role in the homeostasis of histone acetylation and gene transcription. Histone hypoacetylation and transcriptional dysfunction have been identified in a large number of neurological diseases, including ischemic and hemorrhagic stroke. HDAC inhibitors (HDACi) have emerged as a promising therapeutic intervention in neurodegenerative disorders. Here we review and discuss recent observations in the application of the HDACi to combat the effects of stroke in animal and cell culture models. These agents raise histone acetylation levels, adjust the transcription of associated genes, and exert neuroprotective benefits against stroke. Clinical randomized trials should be performed to further investigate the benefits of HDACi for stroke patients.
Export Options
About this article
Cite this article as:
Lv Lei, Tang Yu-Ping, Han Xiang, Wang Xin and Dong Qiang, Therapeutic Application of Histone Deacetylase Inhibitors for Stroke, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152411796011330
DOI https://dx.doi.org/10.2174/187152411796011330 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NADPH Oxidase and Neurodegeneration
Current Neuropharmacology The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Changes in Peripheral Blood Biomarkers with Aging and Neurodegenerative Disorders
Current Aging Science IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Preface
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti-Inflammatory Lipid Mediator)
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Neurodegeneration with Dementia: From Fundamentals of Pathology to Clinical Imaging by MRI and SPECT.
Current Medical Imaging Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease
Current Drug Metabolism Functions of S100 Proteins
Current Molecular Medicine Molecular Mechanisms of Neurotoxicity of Pathological Prion Protein
Current Molecular Medicine Contribution of Inflammatory Processes to Nerve Cell Toxicity by Bilirubin and Efficacy of Potential Therapeutic Agents
Current Pharmaceutical Design Meet Our Associate Editor
Current Molecular Medicine Human Embryonic Stem Cell Therapies for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Fighting Against Alzheimer's Disease: Synthesis of New Pyrazoline and Benzothiazole Derivatives as New Acetylcholinesterase and MAO Inhibitors
Letters in Drug Design & Discovery Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery